The analyses of BCMA and PD1/PDL1 expression performed here confirmed that anti-BCMA mAbs and BCMA×PDL1 bsAbs may be useful therapeutic drugs not only for MM but also for a proportion of more differentiated B-NHL, which in some cases express BCMA to a similar degree as MM cells, at least after the inhibition of ɣ-secretase. This evidence concerns the gene PDCD1 and Miyoshi myopathy.